Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin.

European journal of clinical pharmacology - 1 Aug 2009

Fuchshuber-Moraes Mateus, Perini Jamila A, Rosskopf Dieter, Suarez-Kurtz Guilherme

Abstract excerpt

PURPOSE: To explore the pharmacogenomics of warfarin using the extreme-discordant-phenotype (EDP) methodology. METHODS: The target phenotype was the stable warfarin dose prescribed to 353 patients. Pharmacogenetic polymorphisms assessed were coagulation factor VII (FVII) -401G>T and FVII -402G>A, VKORC1 3673G>A, and CYP2C9*2, *3, *5, and *11 alleles. The EDP analyses contrasted the frequencies of these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Black People

Share to Cytochrome P-450 CYP2C9

Share to Factor VII

Share to Mixed Function Oxygenases

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 19387626
DOI: 10.1007/s00228-009-0651-6

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin.PMID 19387626Read ↗

Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.Semantic proximity Read ↗

Warfarin pharmacogenetics.Semantic proximity Read ↗

Identification of novel variants associated with warfarin stable dosage by use of a two-stage extreme phenotype strategy.Semantic proximity Read ↗

Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.Semantic proximity Read ↗

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.Semantic proximity Read ↗

Warfarin pharmacogenomics.Semantic proximity Read ↗

Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.Semantic proximity Read ↗

Genome-wide association study of warfarin maintenance dose in a Brazilian sample.Semantic proximity Read ↗

Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups.Semantic proximity Read ↗

Warfarin Pharmacogenomics in Diverse Populations.Semantic proximity Read ↗

Estimation of the warfarin dose with clinical and pharmacogenetic data.Semantic proximity Read ↗

An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.